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Given the detrimental interaction be-
tween both pathogens, visceral leishman-
iasis (VL)–HIV co-infection has been
identified as one of the emerging chal-
lenges for VL control [1]. The epidemio-
logical impact of HIV on VL was most
strikingly illustrated by the effect of the
HIV epidemic in VL-endemic countries in
southern Europe, with HIV contributing
to the re-emergence of VL. By early 2000,
almost 2,000 cases of VL–HIV co-infec-
tion (predominantly in intravenous drug
users) had been identified, with up to
50%–60% of all VL cases being HIV co-
infected [2]. Fortunately, with the wide-
scale introduction of highly active antiret-
roviral therapy (ART), a gradual decline in
VL incidence has been observed in
Europe over the last decade [1,3]. Cur-
rently, the burden of VL–HIV co-infec-
tion is most apparent in some regions in
East Africa, like Northwest Ethiopia,
where between 20%–40% of VL cases
are co-infected with HIV [1]. The prob-
lem also seems to be emerging in India
and Brazil [1].
There is abundant evidence that HIV
strongly affects VL treatment response,
including in the East African setting.
Initial parasitological failure rates are
typically below 2%–3% in immunocom-
petent individuals, but can be as high as
50% in co-infected patients [4]. Case
fatality rates in East Africa are 3–9-fold
higher in HIV co-infected patients, reach-
ing up to 15%–33% [1,5]. Whereas
relapses are uncommon (,5%) in immu-
nocompetent individuals, this can reach
50%–60% by one year in some high-risk
HIV co-infected individuals [1,6]. ART is
apparently only partially protective against
relapse [6]. Importantly, repeated relapses
tend to become increasingly unresponsive
to treatment, and secondary prophylaxis is
often required until sufficient CD4 cell
count recovery has taken place (at least in
areas with zoonotic transmission) [1].
At an early stage, several meetings on
VL–HIV co-infection were organized by
the World Health Organization (WHO)
trypanosomiasis and leishmaniasis unit
(Division of Tropical Diseases), and an
international surveillance system was put
in place. Based on the evidence available,
VL was proposed—in 1995—as an Ac-
quired Immunodeficiency Syndrome
(AIDS)–defining condition requiring
ART initiation irrespective of CD4 counts
[7], and this has remained so since then
(see Table 1) [8]. VL is now included as an
AIDS-defining condition in virtually all
VL-treatment guidelines for use in coun-
tries where VL–HIV is prevalent.
Early on in the HIV epidemic—in
1990—WHO developed an HIV clinical
staging system adopted for use in low- and
middle-income countries [9]. This WHO
clinical staging system is widely used by
the HIV medical community and forms
the backbone of several important recom-
mendations like cotrimoxazole prophylaxis
and eligibility for ART. It has undergone
several adaptations over the years, with
the latest revision of the WHO staging
system reported in 2007 [10]. This clinical
staging system has also systematically been
endorsed across all revised WHO ART
guidelines over the last 10 years, up to the
most recent version in 2013 [11–14].
Surprisingly, and in contrast with the
latest recommendations coming out of the
WHO Department of Neglected Tropical
Disease and the WHO Expert Committee
on the Control of Leishmaniases, VL is not
systematically included as an AIDS-defin-
ing condition. Although VL appeared in
the interim revised clinical staging recom-
mendations (as a WHO stage 4 condition),
the finalized version (2007) only stated
‘‘atypical disseminated leishmaniasis’’ as a
stage 4 condition, and this was included in
the 2006, 2010, and 2013 ART guidelines.
This term (atypical disseminated leishman-
iasis) is not clearly defined, with no
presumptive clinical diagnosis proposed
and as definitive diagnosis: ‘‘… histology
(amastigotes visualized) or culture from
any appropriate clinical specimen.’’ Dis-
seminated cutaneous leishmaniasis is an
established clinical entity, but ‘‘atypical
disseminated leishmaniasis’’ is not. Strictly
speaking, it is not even clear whether both
VL and cutaneous leishmaniasis would be
considered.
Similarly to tuberculosis–HIV co-infec-
tion, successful management and control
of VL–HIV co-infection will hinge on the
effective coordination of both VL and
HIV programs [15]. Coordination at the
global level is likely to foster successful
integration of national programs [15]. For
instance, in Ethiopia—which has the
highest VL–HIV co-infection rates—the
national VL guidelines recommend rou-
tine ART for all VL cases, but the HIV/
ART guidelines will follow the interna-
tional HIV clinical staging system (only
mentioning ‘‘atypical disseminated leish-
maniasis;’’ http://www.who.int/hiv/pub/
guidelines/ethiopia_art.pdf). The same is
true in other VL-endemic countries such
as India and Uganda. In contrast, VL is an
AIDS-defining condition in the national
ART guidelines in Brazil and Kenya. As
to Sudan and South Sudan, both ‘‘atypical
disseminated leishmaniasis’’ and VL are
included. We call upon WHO to address
this inconsistency and hope this can be
rectified by the next revision of the WHO
guidelines.
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Table 1. Overview of integration of visceral leishmaniasis as an AIDS-defining condition in WHO guidelines.
Year HIV/AIDS Program Control of Tropical Diseases/NTD
1990 WHO clinical staging of HIV: No mention of VL
1995 Consultative meeting on Leishmania-HIV co-infection: ‘‘Leishmania: AIDS-defining
disease: any patients with co-existing HIV-infection and VL’’
2003 WHO clinical staging in 2003 ART guideline: No mention of VL
2005 Interim guideline WHO clinical staging (Africa): visceral leishmaniasis
(stage 4)
2006 WHO clinical staging in 2006 ART guideline: Atypical disseminated
leishmaniasis (stage 4)
2007 Revised WHO clinical staging: Atypical disseminated leishmaniasis
(stage 4)
5th Consultative Meeting on Leishmania-HIV Co-infection: ‘‘VL is an AIDS-defining
condition,… to start ART, irrespective of CD4 count’’
2010 WHO clinical staging in 2010 ART guideline: Atypical disseminated
leishmaniasis (stage 4)
WHO guideline on Leishmaniasis (2010): VL: AIDS-defining condition; …starting
antiretroviral treatment, irrespective of CD4 count
2013 WHO clinical staging in 2013 ART guideline: Atypical disseminated
leishmaniasis (stage 4)
AIDS: Acquired Immunodeficiency Syndrome; ART: antiretroviral treatment; NTD: neglected tropical diseases; VL: visceral leishmaniasis; WHO: World Health
Organization.
doi:10.1371/journal.pntd.0002916.t001
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